Actively Recruiting
Study of Venetoclax and Azacitidine Treatment in Adults Aged 60 to 90 with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy
Led by University Hospital, Caen · Updated on 2025-02-28
100
Participants Needed
1
Research Sites
47 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying adults aged 60 to 90 years with newly diagnosed acute myeloid leukemia AML who are not eligible for intensive chemotherapy. The study aims to compare the average leftover levels of the drug venetoclax in the blood between patients who achieve complete remission and those who do not after the first treatment cycle. This observational study follows standard care practices and involves patients treated with venetoclax combined with azacitidine. Participants receive venetoclax orally at 400 mg per day after a three-day dose increase phase, along with intravenous azacitidine at 75 mgm on days 1 to 7 of each cycle. Patients are grouped based on whether they achieve complete remission after the first cycle. Blood samples are collected multiple times to measure venetoclax and antifungal drug levels throughout the treatment period. During the study, patients undergo regular blood sampling via venous and capillary punctures to monitor drug concentrations and other health parameters. Researchers will evaluate the relationship between venetoclax levels and remission, study survival rates, early deaths, and adverse events over 24 months. The study also examines the variability in drug levels and factors that may influence treatment outcomes, all while patients receive their usual care.
CONDITIONS
Brief Title
Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX)
Research Team
S
Sylvain Chantepie, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here